Casala AM, Alezzandrini AA. Vitiligo, poliosis unilateral con retinitis pigmentaria y hypoacusia. Arch Argent Dermatol. 1959. 9:449.
Alezzandrini AA. [Unilateral manifestations of tapeto-retinal degeneration, vitiligo, poliosis, grey hair and hypoacousia]. Ophthalmologica. 1964. 147:409-19. [Medline].
Barnes L. Vitiligo and the Vogt-Koyanagi-Harada syndrome. Dermatol Clin. 1988 Apr. 6(2):229-39. [Medline].
Vogt A. Fruhzeities ergraven der zilien und bemerkungen uber den sogenannten plotzlichen einendieser veranderugn. Klin Monatsbl Augenheilkd. 1906. 44:228.
Gilbert W. Vitiligo und Auge, ein Beitrag zur Kenntnis der herpetischen augeenerkran kunger. Klin Monatsbl Augenheilkd. 1910. 48:24.
Harada E. Clinical study of nonsuppurative choroiditis: A report of acute diffuse choroiditis. Acta Soc Opthalmol Jpn. 1926. 30:356.
Koyanagi Y. Dysakusis, Alopecia, und Poliosis beschwerer Uveitis nicht traumatischen Ursprunge. Klin Monatsbl Augenheilkd. 1929. 82:194.
Kodjikian L, Seve P, Le Hoang P, Garweg JG. Atypical Vogt-Koyanagi-Harada disease or new uveomeningitic syndrome?. Graefes Arch Clin Exp Ophthalmol. 2005 Mar. 243(3):263-5. [Medline].
Cervantes J, Price A, Oberlin K, Rosen A. Progressive Depigmentation in a Patient with Panuveitis and Meningitis. Skin Appendage Disord. 2018 Jan. 4 (1):12-14. [Medline].
Austin D, Moore JS, Gangaputra S. Vogt-Koyanagi-Harada Syndrome: A Rare Cause of Panuveitis Presenting as Unilateral Loss of Visual Acuity. J Clin Rheumatol. 2020 Feb 22. [Medline].
Du L, Yang P, Hou S, Lin X, Zhou H, Huang X, et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2008 Apr. 127(1):43-8. [Medline].
Li H, Liu Q, Hou S, Du L, Zhou Q, Zhou Y, et al. TNFAIP3 gene polymorphisms in a Chinese Han population with Vogt-Koyanagi-Harada syndrome. PLoS One. 2013. 8(3):e59515. [Medline]. [Full Text].
Hoffman MD, Dudley C. Suspected Alezzandrini's syndrome in a diabetic patient with unilateral retinal detachment and ipsilateral vitiligo and poliosis. J Am Acad Dermatol. 1992 Mar. 26(3 Pt 2):496-7. [Medline].
Shamsadini S, Meshkat MR, Mozzafarinia K. Bilateral retinal detachment in Alezzandrini's syndrome. Int J Dermatol. 1994 Dec. 33(12):885-6. [Medline].
Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013 Sep. 12(11):1033-8. [Medline].
Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009 Jan. 147(1):154-161.e1. [Medline].
Andrade A, Pithon M. Alezzandrini syndrome: report of a sixth clinical case. Dermatology. 2011 Feb. 222(1):8-9. [Medline].
Haque WM, Mir MR, Hsu S. Vogt-Koyanagi-Harada syndrome: Association with alopecia areata. Dermatol Online J. 2009. 15(12):10. [Medline].
A V P, Kumar J S A, K N N, Rao S, Shetty S. Unusual Case of Vogt-Koyanagi-Harada Syndrome Presenting as Non-specific Headache. J Clin Diagn Res. 2014 Apr. 8(4):VD06-VD07. [Medline]. [Full Text].
Khairallah AS. Headache as an initial manifestation of Vogt-Koyanagi-Harada disease. Saudi J Ophthalmol. 2014 Jul. 28(3):239-42. [Medline]. [Full Text].
Lorincz AL. Disturbances of melanin pigmentation. Moschella SL, Hurley JH, eds. Dermatology. Philadelphia, Pa: WB Saunders; 1985.
Rao NA, Gupta A, Dustin L, Chee SP, Okada AA, Khairallah M, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology. 2010 Mar. 117(3):591-9, 599.e1. [Medline]. [Full Text].
Grob A, Grekin S. Piebaldism in children. Cutis. 2016 Feb. 97 (2):90-2. [Medline].
Karadag R, Esmer O, Karadag AS, Bilgili SG, Cakici O, Demircan YT, et al. Evaluation of ocular findings in patients with vitiligo. Int J Dermatol. 2016 Mar. 55 (3):351-5. [Medline].
Gupta M, Pande D, Lehl SS, Sachdev A. Alezzandrini syndrome. BMJ Case Rep. 2011 Aug 17. 2011:[Medline].
Huggins RH, Janusz CA, Schwartz RA. Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol. 2006 Jan-Feb. 72(1):68-71. [Medline].
Saleem MD, Oussedik E, Schoch JJ, Berger AC, Picardo M. Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions. J Am Acad Dermatol. 2019 May. 80 (5):1215-1231.e6. [Medline].
Fukutsu K, Namba K, Iwata D, Mizuuchi K, Kase S, Suzuki K, et al. Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: case report based on multimodal imaging. BMC Ophthalmol. 2020 Mar 10. 20 (1):94. [Medline].
Vasconcelos-Santos DV, Sohn EH, Sadda S, Rao NA. Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings. Retina. 2010 Jan. 30(1):33-41. [Medline].
Zamecki KJ, Jabs DA. HLA typing in uveitis: use and misuse. Am J Ophthalmol. 2010 Feb. 149(2):189-193.e2. [Medline].
Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015. 9:1697-702. [Medline].
Raffa L, Bawazeer A. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane. Can J Ophthalmol. 2009. 44:615-6. [Medline].
Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocul Immunol Inflamm. 2010 Jun. 18(3):218-22. [Medline].
Arcinue CA, Radwan A, Lebanan MO, Foster CS. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. Ocul Immunol Inflamm. 2013. 21(1):47-52. [Medline].
Wand K, Abraham S, Loos D, Stumpfe S, Lohmann C, Maier M, et al. [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome]. Ophthalmologe. 2015 Oct. 112 (10):857-60. [Medline].
Cuevas M, de-la-Torre A, Córdoba A. Bilateral Iris Depigmentation and Ocular Hypotony as End-Stage Manifestations of Untreated Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm. 2017 May 26. 1-6. [Medline].